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Abstract
Background: There is no proven medical approach to attenuating expansion and rupture of abdominal aortic aneurysms
(AAAs). One approach that is currently being investigated is the use of doxycycline. Despite being primarily used as an
antimicrobial drug, doxycycline has been proposed to function in reducing AAA expansion. Doxycycline is effective in
reducing the formation in the most commonly used mouse models of AAAs when administered prior to the initiation of the
disease. The purpose of the current study was to determine the effects of doxycycline on established AAAs when it was
administered at a dose that produces therapeutic serum concentrations.
Methods and Results: LDL receptor 2/2 male mice fed a saturated-fat supplemented diet were infused with AngII
(1,000 ng/kg/min) via mini-osmotic pumps for 28 days. Upon verification of AAA formation by noninvasive high frequency
ultrasonography, mice were stratified based on aortic lumen diameters, and continuously infused with AngII while also
administered either vehicle or doxycycline (100 mg/kg/day) in drinking water for 56 days. Administration of doxycycline led
to serum drug concentrations of 2.360.6 mg/ml. Doxycycline administration had no effect on serum cholesterol
concentrations and systolic blood pressures. Doxycycline administration did not prevent progressive aortic dilation as
determined by temporal measurements of lumen dimensions using high frequency ultrasound. This lack of effect on AAA
regression and progression was confirmed at the termination of the study by ex vivo measurements of maximal width of
suprarenal aortas and AAA volumes. Also, doxycycline did not reduce AAA rupture. Medial and adventitial remodeling was
not overtly changed by doxycycline as determined by immunostaining and histological staining.
Conclusions: Doxycycline administration did not influence AngII-induced AAA progression and aortic rupture when
administered to mice with established AAAs.
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Introduction
Abdominal aortic aneurysms (AAAs) represent a progressive
disease state with a life-threatening but unpredictable risk for
rupture [1]. Currently, no pharmacological intervention has been
demonstrated to effectively inhibit the progressive expansion of
human AAAs or prevent aortic rupture [2]. One well-recognized
characteristic in human AAAs is the increased abundance and
activation of matrix metalloproteinases (MMPs) in the diseased
aortic tissues [3–5].
MMPs are a family of zinc-dependent endopeptidases that are
expressed in many cell types. MMPs have been linked to the
development of AAAs due to their ability to degrade many
extracellular matrix proteins, including elastin and collagen. This
associative link of MMPs to AAAs has been enhanced by the
detection of many different MMPs in human and experimental
aneurysmal tissues, including MMP-1, -2, -3, -7, -8, -9, -12, -13,
and MT1-MMP [6–11]. A direct role of MMPs on experimental
AAAs has been implicated by mouse models with genetic deletion
of MMP-2, MMP-9, MMP-12, or MT1-MMP [12–15]. For
example, deficiency of any of these genes in mice attenuates
calcium chloride-induced AAAs [12–14], and deficiency of MMP-
9 reduces elastase-induced AAAs [15]. However, given the
expression of multiple MMPs in aneurysmal tissues and their
overlapping substrate selectivity, it has been proposed that an
optimal therapeutic strategy in humans would be a drug that
broadly inhibits a spectrum of MMPs. Since doxycycline has this
property, it has been advocated as a clinically beneficial drug for
patients afflicted with AAAs [16].
All three of the commonly used mouse AAA models (elastase-
[15], calcium chloride- [12], and angiotensin II (AngII)-induced
[17] AAAs) have augmented MMP activation [18]. Furthermore,
doxycycline attenuates the formation of experimental AAAs in
these mouse models [15,19,20]. In these studies, doxycycline was
administered prior to application of the initiating event that led to
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AAA formation. However, in a clinical setting, medical therapy
would be initiated following the detection of an established AAA.
Consequently, efficacy of potential therapeutic strategies needs to
be determined on the effects of progression. AngII infusion for 28
days leads to the formation of AAAs, which have complex
pathology [21–23]. Continuous infusion beyond 28 days results in
progressive AAA expansion and tissue remodeling [24]. Therefore,
in the present study, we determined the effects of doxycycline on
the progression of established AAAs in mice with prolonged
infusion of AngII. Despite achieving serum drug concentrations
comparable to those in clinical trials, we were unable to detect an
effect of doxycycline on established AAAs.
Materials and Methods
Mice and Diet
Male LDL receptor 2/2 mice on a C57BL/6 background
were purchased from The Jackson Laboratory (Stock number
002207, Bar Harbor, Maine, U.S.A.). Mice were housed under
barrier conditions and fed normal rodent laboratory diet and
water ad libitum. One week prior to mini-osmotic pump
implantation, all mice were fed a diet containing milk fat (21%
wt/wt) and cholesterol (0.2% wt/wt; TD.88137, Harlan Teklad,
Madison, WI, U.S.A.).
AngII Infusion and Administration of Doxycycline
Mini-osmotic pumps (Alzet Model 2004, Durect Corp,
Cupertino, CA, U.S.A.) were implanted subcutaneously to deliver
AngII (1,000 ng/kg/min; catalog number A9525, Sigma-Aldrich,
St. Louis, MO, U.S.A.) as described previously [17,25]. Prior to
and 24 days after pump implantation, lumen diameters of
suprarenal aortas were measured in all mice using a Vevo 660
ultrasound (Visualsonics, Toronto, Ontario, Canada). Mice with
established AAAs ($50% increase of maximal lumen diameter
compared to baseline diameter in the suprarenal aorta) were
implanted with new mini-osmotic pumps at day 28 and the pumps
were replaced at day 56 to permit continuous delivery of AngII for
another 56 days. At the 28-day interval, mice were stratified into 2
groups with equivalent sized AAAs. One group was provided with
drinking water alone (vehicle), and the other group was
administered doxycycline (catalog number D9891, Sigma-Aldrich,
St. Louis, MO, U.S.A.). Doxycycline hyclate was dissolved in
drinking water at a dose of 100 mg/kg/day and prepared fresh
daily. Water bottles containing doxycycline solutions were covered
with aluminum foil to protect from light [20].
Ultrasound Measurement
Lumen diameters of suprarenal aortas were measured using a
Vevo 660 ultrasound imaging system in a real-time pattern as
described previously [22]. Two-dimensional images (B mode) of
short-axis scan were acquired to determine the maximal diameters
of suprarenal aortas at selected intervals (weeks 0, 4, 7, and 12
during AngII infusion).
Systolic Blood Pressure Measurement
Systolic blood pressures were measured on conscious mice using
noninvasive tail-cuff systems (BP-2000; Visitech Systems, Inc.,
Apex, NC, U.S.A.; or CODA 6; Kent Scientific Corp, Torrington,
CT, U.S.A.) as described previously [26]. Systolic blood pressures
were measured 1 week before mini-osmotic pump implantation to
record baseline blood pressures, and repeated on weeks 4, 6, 8, 10,
and 12 during AngII infusion.
Serum Cholesterol and Drug Concentration
Measurement
Serum cholesterol concentrations were determined using an
enzymatic assay kit (Cholesterol E, catalog number 439-17501,
Wako Chemicals USA, Inc., Richmond, VA, U.S.A.) as described
previously [27]. Serum doxycycline concentrations were measured
using reverse-phase high performance liquid chromatography with
UV detection as described previously [28].
AAA Quantification
During termination, aortas were excised after pressure perfusion
at 100 mmHg with 10% neutrally buffered formalin and injected
with 3% (wt/vol) agarose to maintain patency. AAAs were
quantified by measuring ex vivo maximal diameter of suprarenal
aortas using Image-Pro Plus software (Media Cybernetics,
Bethesda, MD, U.S.A.) [29]. Volume of each AAA was measured
using the three-dimensional imaging function of the Vevo 660
ultrasound.
Histological Staining and Immunostaining
Abdominal aortas containing AAAs were serially cross-sectioned
(10 mm thick/section) from the proximal to the distal as described
previously [21,24]. Collagen content was determined with
picrosirius red staining. Immunostaining was performed to identify
macrophages and smooth muscle cells as described previously
[30]. The following primary antibodies were used: rabbit antisera
against mouse macrophages (Catalog number AIAD31240,
Accurate Chemical & Scientific Corp, Westbury, NY, U.S.A.)
and rabbit polyclonal antibody against alpha smooth muscle actin
(catalog number ab5694, Abcam, Cambridge, MA, U.S.A.).
Statistical Analysis
Data are presented as means 6 standard error of means (SEM).
SigmaPlot version 12 (Systat Software Inc., San Jose, CA, USA)
was used for statistical analyses. Two-group comparisons were
performed using Student’s t test for normally and equally
distributed data and Mann-Whitney Rank Sum analysis for data
having failed either normality or equal variance test. Weekly body
weight, systolic blood pressure, and aortic diameters measured at
selected time points with ultrasound were analyzed using two way
repeated measures ANOVA. Aortic rupture rate during prolonged
AngII infusion (Days 28–84) was compared between the two
groups (Vehicle versus Doxycycline) using LogRank survival
analysis. A P,0.05 was considered to be significant.
Ethics Statement
All mouse studies were performed with approval of the
University of Kentucky Institutional Animal Care and Use
Committee (IACUC protocol number: 2006-0009).
Results
Characteristics of Study Mice
Forty-one male LDL receptor 2/2 mice were infused with
AngII (1,000 ng/kg/min) for 28 days before these mice were
administered either the vehicle or doxycycline. During the 28-day
infusion with AngII, 9 mice (22%) died of aortic rupture. AAA
formation was confirmed in 25 of the remaining 32 mice (78%) by
ultrasound at day 24 of AngII infusion. Subsequently, mice with
established AAAs (N = 25) were stratified to receive vehicle
(N = 11) or doxycycline (N = 14) 28 days after AngII infusion.
Doxycycline given in drinking water was well tolerated as
determined by daily observation and body weight measurements
Doxycycline and AAA Regression
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on a weekly base. Oral administration of doxycycline at a dose of
100 mg/kg/day led to serum drug concentrations of 2.360.6 mg/
ml as measured using reverse-phase high performance liquid
chromatography (Figure 1). In mice infused with AngII for a
prolonged interval, doxycycline administration had no effects on
body weight, systolic blood pressure (Figure 2), and serum
cholesterol concentrations (vehicle versus doxycycline: 1429661
and 1227697, respectively; P.0.05).
Doxycycline Did Not Regress or Prevent the Progression
of AngII-induced AAAs
Protracted AngII infusion led to progressive luminal expansion
of suprarenal aortas as monitored by ultrasonography (Figure 3),
which was consistent with our previous report [24]. Doxycycline
did not attenuate the expansion rate of suprarenal aortic diameters
measured temporally with ultrasound. This lack of effect as
determined by the noninvasive imaging was confirmed after
termination by ex vivo maximal width of suprarenal aortas
(Figure 4A). Furthermore, three-dimensional AAA imaging
reconstruction demonstrated that doxycycline did not change
AAA volume (Figure 4B). In addition, doxycycline did not
influence the incidence of death caused by aortic rupture as
determined by necropsy (Figure 5).
Doxycycline Did Not Change Cellular and Extracellular
Characteristics of AAA Tissues
Pathologies of AngII-induced AAAs in advanced stages are
highly heterogeneous, exhibiting complex features and differing
markedly along the length of a single aneurysm [21,24]. To
determine whether broad inhibition of MMPs by doxycycline
influenced pathological characteristics, AAAs were serially cross-
sectioned throughout the region of aortic expansion. Consistent
with our previous study [24], prolonged AngII infusion resulted in
transmedial rupture that occurred predominantly at the left
anterior aspect of the suprarenal aortic region. Profound
neovascularization was present in adventitia as demonstrated by
positive smooth muscle alpha-actin staining, particularly sur-
rounding the regions of medial rupture. Pronounced accumulation
of macrophages was detected in both aortic aneurysmal tissues and
the adventitia surrounding the AAA. Cellular elements and
collagen deposition were markedly heterogeneous even within a
single aneurysm. There was no overt difference in the cellular and
matrix contents in AAAs between mice administered vehicle and
doxycycline (Figures 6 and 7).
Discussion
Doxycycline suppresses formation of experimental AAAs as
demonstrated in both rat and mouse models [3,15,19,20,31–36].
In all these studies, doxycycline was administered during the
initiative phase of AAAs. In contrast as shown in the present study,
doxycycline did not influence established AAAs in AngII-infused
hypercholesterolemic mice, although effective serum concentra-
tions of the drug were achieved. Additionally, doxycycline did not
change either aortic rupture rate or pathological characteristics of
AngII-induced AAAs.
While doxycycline is a widely used antibiotic, it is also a well-
recognized broad-spectrum inhibitor of MMPs. It has been
Figure 1. Measurements of serum doxycycline concentrations.
Serum doxycycline concentrations were measured using reverse-phase
high performance liquid chromatography. Histobars represent means,
and error bars represent SEM (N = 9 in vehicle group and N = 10 in
doxycycline group). * denotes P,0.001 by Mann-Whitney Rank Sum
analysis.
doi:10.1371/journal.pone.0046411.g001
Figure 2. Doxycycline did not change AngII-induced increases
of systolic blood pressures. Systolic blood pressures were measured
using a tail-cuff system prior to pump implantation (week 0) and at
weeks 4, 6, 8, 10, and 12 during AngII infusion. Vehicle or doxycycline
administration in drinking water started after 4 weeks of AngII infusion.
Circles represent mean values at each time point and bars represent
SEM. N = 9 and 10 for vehicle and doxycycline groups, respectively.
Statistical analysis was performed using two way repeated measures
ANOVA. P,0.001 for the comparisons of the AngII infusion interval.
P = 0.50 for the comparisons between the two groups.
doi:10.1371/journal.pone.0046411.g002
Figure 3. Doxycycline did not reduce lumen expansion rates of
AngII-induced AAAs. Maximal luminal diameters of suprarenal aortas
were measured by ultrasonography prior to (week 0) and at weeks 4, 7,
and 12 during AngII infusion. Circles represent mean values of each
time point and bars represent SEM. N = 9 in vehicle group and N = 10 in
doxycycline group. Statistical analysis was performed using two way
repeated measures ANOVA. P,0.001 for the comparisons of the AngII
infusion interval. P = 0.71 for the comparisons between the two groups.
doi:10.1371/journal.pone.0046411.g003
Doxycycline and AAA Regression
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reported that doxycycline reduces experimental AAAs via
inhibiting MMP activation [15,19,31,33,34,36]. In our [20] and
a recently reported [36] studies, doxycycline at a dose of 30 mg/
kg/day was provided in drinking water during subcutaneous
infusion of AngII for 4 weeks. This dose of doxycycline profoundly
reduced AngII-induced AAAs and the rate of aortic rupture
[20,36]. In the present study, we administered doxycycline at a
dose of 100 mg/kg/day in drinking water in order to achieve
maximal inhibitory effects on MMP activation [19]. This dose has
been demonstrated to efficiently inhibit MMP activation in AAA
tissues from humans and animal models [19,35]. In the present
study, this dose and the mode of administration resulted in a mean
serum doxycycline concentration of 2.3 mg/ml that is within the
effective range to inhibit MMP activity [19,35]. Despite achieving
effective serum concentrations, doxycycline had no effect on
established AAAs in AngII-infused mice as measured by several in
vivo and ex vivo modalities. During AngII infusion and
doxycycline administration, luminal expansion of suprarenal
aortas was monitored using ultrasonography. We observed
equivalently progressive luminal dilation in both the vehicle and
doxycycline administered mice. In vivo ultrasonic measurements
prior to termination were confirmed to be comparable with the ex
vivo aortic width measurements of suprarenal aortas. We also
measured volume of each AAA and obtained similar results as the
other measurements between the two groups. These different
approaches provided compelling evidence that doxycycline did not
influence the size of established AAAs in AngII-infused hypercho-
lesterolemic mice. Aortic rupture, the devastating consequence of
AAAs that occurred in nearly any stage during AAA progression,
was not significantly influenced by administration of doxycycline
during the protracted AngII infusion.
AAA diameter is the most commonly used parameter to
monitor the progression of AAAs and is also used to represent the
risk for aortic rupture in patients [2]. A growing body of evidence
provides mechanistic insights that progression of AAAs and the
Figure 4. Doxycycline did not change aortic widths or lumen
volumes of AngII-induced AAAs. (A) Maximal external widths of
suprarenal aortas were measured using Image-Pro Plus software. (B)
Volumes of suprarenal aortas were measured on three-dimensional
reconstructed images of ex vivo AAAs. Circles represent the values of
individual mice (N = 9 in vehicle group and N = 10 in doxycycline group),
diamonds represent means, and bars are SEM. Student’s t test was
performed to compare the two groups for both aortic widths and
lumen volumes. P = 0.97 and 0.72, respectively.
doi:10.1371/journal.pone.0046411.g004
Figure 5. Doxycycline did not influence deaths caused by
aortic rupture. Mouse number after excluding dead mice due to
aortic rupture was recorded from the beginning of doxycycline
administration (day 28 during AngII infusion) to the termination of
study mice (day 84 during AngII infusion). Each line represents number
of live mice on each day during AngII infusion. Aortic rupture rate
between the two groups was analyzed using LogRank survival analysis.
P = 0.65.
doi:10.1371/journal.pone.0046411.g005
Figure 6. Examples of AngII-induced AAAs in an LDL receptor
2/2 mouse administered vehicle. (A)–(D) Heterogenous patho-
logical features of the AAA from the proximal to the distal as shown by
immunostaining of alpha smooth muscle actin. (E) Volume of the AAA
was measured using the 3-dimensional imaging function of a Vevo 660
ultrasound.
doi:10.1371/journal.pone.0046411.g006
Doxycycline and AAA Regression
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potential to rupture may be driven by complex pathological
features, rather than being simply associated with increases of
aneurysmal size. Hence, in addition to the quantification of AAA
size by multiple processes, we also characterized AAAs with
histological and immunological stainings. In agreement with our
recent report [24], prolonged infusion of AngII resulted in
progressively disorganized extracellular matrix, transmural tissue
remodeling, and extensive macrophage accumulation in both
aneurysms and the adventitia surrounding AAAs. We were unable
to distinguish any difference in the pathology of aneurysms in
aortic tissues retrieved from vehicle versus doxycycline adminis-
tered mice. In addition to macrophage infiltration, neutrophils (as
determined by immunostaining of myeloperoxidase) and cytotoxic
(CD8+) T lymphocytes are abundant in human AAA tissue [37].
The numbers of these cell types were equivalently reduced by 2
weeks of administering doxycycline at doses of 50–300 mg/day
[37]. In contrast to these human studies, we have not been able to
detect neutrophils in AngII-infused AAAs in mice, although both
T and B lymphocytes are present [17,21]. Their functional role is
unclear since deficiency of both T and B lymphocytes has no effect
on the formation of AAAs during 28 days of AngII infusion [38]. It
remains to be determined whether total lymphocyte deficiency has
an effect on progression of established AAAs.
Although many studies have demonstrated that some drugs and
genetic deletions ameliorate the initiation of AAAs [39], only JNK
inhibition has been reported to cause regression of established
experimental AAAs [40]. An early event during the initiation of
AngII-induced AAAs is transmural medial rupture that leads to
large lumen expansions [21,22]. Therefore, the initial process
requires the destruction of extracellular matrix to enable AAA
formation. Doxycycline prevents the development of AngII-
induced AAAs [20,36], but does not influence AAA size and
rupture in mice with established AAAs. MMP activity might be
compatible with the rapid destruction of extracelluar matrix in the
formative stage and explain the previous demonstration of
doxycycline reducing AAAs in this stage. Following the initiation
of AngII-induced AAAs, continuous infusion leads to slower and
progressive lumen expansion that is accompanied by tissue
remodeling. This phase is characterized by complex changes in
extracellular matrix [21,24]. These temporal changes in tissue
characteristics are consistent with the mechanisms in the
progression phase, but differ dramatically from the initiative
phase. Consequently, there is likely to be disparities in drug effects
at different phases of AAAs. Considering the deleterious damage
and complex remodeling of the aortic wall, it is also possible that
doxycycline may not be effectively delivered to the diseased aorta.
The effects of doxycycline on AAAs have previously been
reported in humans. A small clinical trial involving 32 patients
received either placebo or doxycycline (150 mg daily) for 3 months
and AAA diameter was followed for 18 months [41]. Although
interim analyses observed reduction of AAA expansion in patients
that received doxycycline, there was no effect at the 18 month end
point of the trial. Another small trial of 36 patients also failed to
demonstrate that doxycycline (200 mg daily) influenced AAA
diameter over a 6-month interval [42]. The shortcomings, such as
small number of patients and too short period of the drug
administration, of these pilot studies have been addressed in 2
ongoing clinical trials (NCT00538967and [16]). Although these
pitfalls may attribute to the negative results, it is also possible, as
inferred by the present study, that inhibition of MMPs via
administering doxycycline may not influence established AAAs.
In conclusion, although doxycycline prevents the initiation of
AngII-induced AAAs, it does not retard or obviate the progression
of AAAs, or prevent rupture once AAAs have established. While
MMPs may play a divergent role in the initiative and progressive
stages of AAAs, further studies are necessary to define the
molecular mechanisms that are responsible for the progression of
AAAs before effective therapeutic strategies may be explored for
established AAAs.
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